USAGE OF BACILLUS CLAUSII IN CHRONIC PANCREATITIS
DOI:
https://doi.org/10.11603/1811-2471.2018.v0.i1.8615Keywords:
chronic pancreatitis, dysbiosis, large intestine microflora, Bacillus Clausii.Abstract
The results of the study of large intestine microbiocenosis in patients with chronic pancreatitis with excretory function insufficiency are discussed in the article. 21 patients with chronic pancreatitis aged from 38 to 51 years were included to the study. Inclusions criteria were patients, whom the substitution enzyme therapy hadn’t led to complete improvement of the disease clinical course – there was a violation of the stool, namely unformed feces more than 2 times per day, flatulence. The composition of microbial flora in patients with chronic pancreatitis were evaluated before treatment and after correction of large intestine microbial composition violations to include Bacillus clausii for 10 days on the background of standard therapy – pancreatin 25000 in the minimicrosphere form during each food intake and proton pump inhibitor – omeprazole 20mg in the morning before food intake.
Violation of the large intestine microflora was observed in 95 % of the patients with chronic pancreatitis: I degree dysbiosis in 28.57 % of patients, II degree dysbiosis degree in 42.85 %, and III degree dysbiosis in 23.8 %. Inclusion in the treatment of Enterogermina forte promotes improvement of microbiocenosis of the large intestine, along with the improvement of the clinical course of the disease. The significant restoration of the intestinal microflora was observed in 71 % of patients – namely, increase in bifidobacteria and lactobacilli levels, decrease in total and with poorly expressed enzymatic properties E.coli, and Klebsiela pneumonia, Enterobacter. After treatment, the manifestations of dysbiosis were observed in 29 % of patients: 19 % had I degree dysbiosis and 10 % had II degree dysbiosis.
Conclusions. 1. Violation of large intestine microbiocenosis was accompanied with different degrees of dysbiosis in 95 % of the patients with chronic pancreatitis. 2. Inclusion of Enterogermina forte (1 vial per day for 10 days) in standard therapy leads to the improvement of the clinical course, namely normalization of the defecation, disappearance of flatulence.
References
Vinokurova, L.V., Dubtsova, E.A., Popova, T.V. (2012). Funktsionalnaya nedostatochnost podzheludochnoy zhe- lezy pri khronicheskom pankreatite: fermentozamestitel- naya terapiya, lechebnoe pitanie [Functional pancreatic insufficiency in chronic pancreatitis: enzyme replacement therapy, therapeutic nutrition]. Lechashchiy vrach. Gastro enterologiya – Doctor in Charge. Gastroenterology, 2, 39-44 [in Russian].
Hubergrits, N.B., Lukashevich, G.M, Belyaeva, N.V. (2012). Vozmozhnosti preparata “Oktra” v kupirovanii ab- dominalnoy boli pri khronicheskom pankreatite [Opportu- nities of the drug "Oktra" in abdominal pain relief in chro- nic pancreatitis]. Suchasna hastroenterolohiia – Modern Gastroenterology, 4 (66), 55-62 [in Russian].
Gubergrits, N.B., & Khristich, T.N. (2000). Kliniches kaya pancreatologiya [Clinical pancreatology]. Donetsk: LLC "Lebid" [in Russian].
Klymenko, A.V. (2011). Analiz prichin khroniches- kogo pankreatita u operirovanykh bolnykh [Analysis of the causes of chronic pancreatitis in operated patients]. Za porozhye med. zhurn. – Zaporozhye Medical Journal, 13 (4), 108-109 [in Russian].
Khristich, T.N. (2011). Khronicheskiy pankreatit: vozmozhnye mekhanizmy razvitiya i khronizatsii [Chronic pancreatitis: possible mechanisms of development and chronization]. Suchasna hastroenterolohiia – Modern Gas troenterology, 1 (57), 98-102 [in Ukrainian].
Chernobrovyi, V.M. (2008). Rol shlunkovoi sekretsii u patohenezi khronichnoho pankreatytu [The role of gast- ric secretion in pathogenesis of chronic pancreatitis]. Bu kovyn. med. visnyk – Bukovyna Medical Journal, 12 (1), 156- 162 [in Ukrainian].
Flint, H.J. (2012). The role of the gut microbiota in nutrition and health. Nat. Rev. Gastroenterol. Hepatol., 9, 577-589.
Nagalingam, N.A., & Lynch, S.V. (2012). Role of the microbiota in inflammatory bowel diseases. Inflamm. Bo wel. Dis., 18, 968-984.
Quigley, E.M. (2011). Commensal bacteria: the link between IBS and IBD? Curr. Opin. Clin. Nutr. Metab. Care, 14, 497-503.
Preidis, G.A., Hill, C., & Guerrant, R.L. (2011). Probi- otics, enteric and diarrheal diseases, and global health. Gastroenterology, 140, 8-14.
Sekirov, I., Russell, S.L., & Antunes, L.C. (2010). Gut microbiota in health and disease. Physiol. Rev., 90, 859- 904.
Simren, М., Barbara, G., & Flint, H. (2013). Intesti- nal microbiota in functional bowel disorders: a Rome foun- dation report. Gut., 62, 159-176.
Kostiukevich, O.I. (2009). Khronichnyi pankreatyt: vid patohenezu do terapii [Chronic pancreatitis: from pathogenesis to therapy]. Rosiiskyi medychnyi zhurnal – Russian Medical Journal, 17, 19, 1283-1288 [in Russian].
